Nb157 CAR T cells

Nb157 CAR T cells are an experimental adoptive cellular immunotherapy developed for the treatment of acute myeloid leukemia (AML). These T cells are engineered to express a chimeric antigen receptor (CAR) featuring a nanobody (Nb157) derived from a llama phage-display library using the Sequentially Tumor-Selected Antibody and Antigen Retrieval (STAR) system. The Nb157 nanobody specifically targets CD13 (aminopeptidase N), a cell surface protein highly expressed on AML blasts and leukemia stem cells (LSCs). Upon binding to CD13, the CAR T cells are activated to release cytotoxic cytokines such as interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α) and undergo degranulation to eliminate tumor cells. Research also explores a bispecific and split CAR (BissCAR) configuration where Nb157 provides the primary activation signal (CD3z) while an anti-TIM3 scFv provides costimulatory signals (CD28 and 4-1BB) to enhance specificity and reduce toxicity to normal hematopoietic stem cells.

Other names

Nb157-CAR T cellsNb-157-CAR T cellsNb 157-CAR T cellsanti-CD13 CAR T cellsanti-CD-13 CAR T cellsanti-CD 13 CAR T cellsCD13 CAR T cellsCD-13 CAR T cellsCD 13 CAR T cells